Gevorg Yaghjyan/LinkedIn
May 20, 2026, 14:13
Gevorg Yaghjyan: Targeting Myostatin in Clinical Trials to Preserve Muscle During Weight Loss
Gevorg Yaghjyan, Project Leader at Parexel, shared a post on LinkedIn:
“Obesity drugmakers chase weight loss. Biohaven is betting on muscles.
GLP-1s deliver weight loss, but trials keep showing a catch: approximately 25-40% of that loss can be lean muscle mass.
Biohaven’s approach: target myostatin in clinical trials to preserve muscle during weight loss.
The hypothesis — better body composition, not just lower weight, drives long-term outcomes.If the data holds, the next obesity trial endpoint might not be pounds lost. It might be muscle retained.
The weight loss race is crowded. The muscle preservation lane is wide open.”
Other posts featuring Gevorg Yaghjyan on Hemostasis Today.
-
Oct 8, 2026, 23:27Shayan Mohammadmoradi: Happy to Be Back at the Midwest Platelet Conference for Its 20th Meeting
-
Oct 8, 2026, 23:18Lorena Arranz: Honoured to Contribute to the 6th Global MPN Symposium
-
Oct 8, 2026, 23:06Denis Oduor: Serving Citizens and Saving Lives Through Blood Donation During National Customer Service Week 2026
-
Oct 8, 2026, 22:51Jan Hartmann: Speaking on Global Trends in Plasma Collection at the 50th Meeting of the Japanese Society of Blood Services
-
Oct 8, 2026, 22:49Akshat Jain: Proud to Announce the Publication of Advances in Sickle Cell Disease
-
Oct 8, 2026, 22:49Ed Shovelin: Extending the Platelet Aggregation Testing Window to 72 Hours
-
Oct 8, 2026, 22:48Abdulla A. Damluji: Anticancer Drugs and Thrombosis Mechanisms, Risk Factors, and Prevention
-
Oct 8, 2026, 22:46Miguel Escobar: My Research on Oral Health and Hemophilia
-
Oct 8, 2026, 22:44ISTH 2027 Abstract Submission Opens November 23